Novel d-enantiomeric peptides derived from d3 and use thereof

Abstract

The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and use thereof.

1 .- 15 . (canceled) 
     
     
         16 . A peptide containing at least one amino acid sequence, wherein the peptide comprises at least 50% D-enantiomeric amino acids and is selected from peptides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO. 10, homologs, fragments and parts of said peptides, polymers of said peptides, and homologs of the polymers. 
     
     
         17 . The peptide of  claim 16 , wherein the peptide is linked to a further substance. 
     
     
         18 . The peptide of  claim 16 , wherein the peptide is capable of being used as a therapeutic agent in medicine. 
     
     
         19 . The peptide of  claim 16 , wherein the peptide is capable of treating Alzheimer's disease. 
     
     
         20 . The peptide of  claim 16 , wherein the peptide is substantially composed of D-amino acids. 
     
     
         21 . The peptide of  claim 16 , wherein the peptide is capable of inhibiting formation of fibrils of amyloid beta peptides. 
     
     
         22 . The peptide of  claim 16 , wherein the peptide is capable of binding to aggregated amyloid beta peptides. 
     
     
         23 . A method for preparing the peptide of  claim 16 , wherein the method involves peptide synthesis or mutagenesis. 
     
     
         24 . A kit, wherein the kit comprises the peptide of  claim 16 . 
     
     
         25 . A pharmaceutical composition, wherein the composition comprises as one of the components thereof the peptide of  claim 16 . 
     
     
         26 . A probe for the identification and quantitative and/or qualitative determination of amyloid beta fibrils and/or amyloid beta oligomers, wherein the probe comprises the peptide of  claim 16 . 
     
     
         27 . A method for the prevention of amyloid beta oligomers and/or amyloid beta peptide aggregates, wherein the method comprises employing the peptide of claim  16 . 
     
     
         28 . A method for the detoxification of toxic amyloid beta oligomers and/or aggregates, wherein the method comprises contacting the oligomers and/or aggregates with the peptide of  claim 16 . 
     
     
         29 . The method of  claim 28 , wherein the amyloid beta oligomers and/or aggregates form amorphous, non-toxic aggregates with the peptide. 
     
     
         30 . A method of preventing Alzheimer's disease, wherein the method comprises administering to a subject in need thereof the peptide of  claim 16 .